Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Proteus Molecular Design Ltd.

Division of Boston Scientific Corp.

Latest From Proteus Molecular Design Ltd.

'Methodical' Blend Therapeutics shuns large A round, to build drug combinations company

Raising money for a new drug development company, Blend Therapeutics has deliberately followed a softly, softly approach to funding, according to its stellar scientific founders. The Watertown, Massachusetts-based company backed by the venture capital firms Flagship Ventures, New Enterprise Associates and NanoDimension, gained $2.8 million in a Series A funding round on 10 January 2012. It will work without a CEO until certain technical hurdles have been overcome.

Cancer Orthopedics

Alkermes' PhII ALKS-5461: new mechanism, opiate receptor modulation, for refractory depression

Alkermes is "excited and surprised" about the positive, and rapid, top-line results from a Phase I/II study of the company’s novel compound ALKS-5461 – using an approach of opiate receptor modulation – for major depressive disorder in patients who have had an inadequate response to standard therapies for clinical depression. The positive data now accelerates immediate initiation of a Phase II study, Richard Pops, chief executive of the company, told Scrip.

Gastrointestinal Neurology

Second pharma deal further validates Interprotein's discovery technology

The Japanese drug discovery venture Interprotein Corp has entered into its second agreement with a major pharma firm in as many months, this time with Takeda for the discovery and optimisation of small molecule inhibitors of protein-protein interaction.

Ajinomoto investigates protein-protein inhibitors in discovery alliance with Interprotein

Ajinomoto has turned to a small private Japanese venture to help it identify novel small molecule inhibitors of protein-protein interaction in an undisclosed therapeutic area.

See All

Company Information